NoToVir is an Italian biotechnology company focused on the development of innovative therapies for HPV-related cancers. Our lead asset, Selisistat, is a first-in-class SIRT1 inhibitor with potential as a targeted radiosensitizer and chemosensitizer.
We aim to address a major unmet medical need by restoring tumor suppressor activity in HPV-driven malignancies through a precision oncology approach. Our development strategy begins with HPV-positive head and neck cancer, with plans to expand across multiple indications where a shared molecular mechanism supports a built-in pipeline.

NoToVir is backed by a multidisciplinary team of scientists, clinicians, regulatory experts, and business advisors with strong experience in oncology drug development.

We are currently preparing a Phase IIb clinical trial and are actively engaging with investors and partners to accelerate Selisistat’s path to market.

NoToVir Srl

Org chart

Teams

Offices

NoToVir Srl

Org chart

Teams

Offices

Related companies